Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112136 | 0.86 | SMN1; SMN2 (0.41) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL5120836 | 0.86 | FOLH1 (0.41) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL29498305 | 0.77 | MAPT (0.54) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL98338 | 0.77 | MAPT (0.54) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL4230593 | 0.76 | ADRB2 (0.49) | — | |
| SCHEMBL5492582 | 0.76 | MAPT (0.53) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL6430534 | 0.75 | ADRB2 (0.48) | — | |
| SCHEMBL5112667 | 0.73 | MEN1 (0.36) | TDP1L3MBTL1HPGDMEN1KMT2A | |
| SCHEMBL30147524 | 0.72 | MAPT (0.65) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL26021326 | 0.72 | MAPT (0.65) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| EP-1525180-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004016578-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | ADRB2, ADRB1, ADRA2A | MAPT 2592/4885CYP2C9 1091/4885CYP2C19 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.